Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06108206 · ClinicalTrials.gov registry record · NA

Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma

A NA study of Glioblastoma and Anaplastic Astrocytoma, sponsored by Columbia University.

Recruiting
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT06108206 is a NA study of Glioblastoma and Anaplastic Astrocytoma that is actively recruiting participants, run by Columbia University. The registered enrollment target is 20 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06108206, a NA study of Glioblastoma and Anaplastic Astrocytoma, is actively recruiting participants, sponsored by Columbia University.

RECRUITING
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to find out if performing additional Magnetic Resonance Image (MRI) scans of the subjects' brain during each week of the radiation treatment of their high-grade glioma will help improve the radiation treatment.

Interventions

  • OTHER Adaptive Radiotherapy

Study Locations (1)

New York

  • Columbia University Irving Medical Center/NYPH - New York

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2024-01-30
Est. Completion 2027-12
Phase NA

Sponsor

Columbia University

958 total trials

What the Registry Record Tells You About NCT06108206

The ClinicalTrials.gov registry entry for NCT06108206 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (82% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which Adaptive Radiotherapy is the first listed.

NCT06108206 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT06108206 about?

NCT06108206 is a clinical study titled "Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma". The purpose of this study is to find out if performing additional Magnetic Resonance Image (MRI) scans of the subjects' brain during each week of the radiation treatment of their high-grade glioma will help improve the radiation treatment.

What is the current status of trial NCT06108206?

This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2024-01-30. Estimated completion is 2027-12.

What conditions does trial NCT06108206 study?

This clinical trial studies the following conditions: Glioblastoma, Anaplastic Astrocytoma, Astrocytoma, Anaplastic Oligodendroglioma.

What interventions are being tested in trial NCT06108206?

The interventions under investigation include: Adaptive Radiotherapy (OTHER).

Who is sponsoring clinical trial NCT06108206?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06108206 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Glioblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.